Key facts
- Starry Gene’s last known valuation is $11.9M (Nov 2020).
- It has raised $4.5M; the latest was Later Stage VC in Sep 2025.
- Notable investors include CAS Star, Hefei Industry Investment Group, Hefei Innovation Technology Venture Capital, Hefei Hi-Tech VC, Co-Win Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Starry Gene
- ·The full record, as it builds
Funding rounds
No funding rounds for Starry Gene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Starry Gene
Developer of genetic modification technologies intended for therapeutic applications in ophthalmic disorders. The company focuses on the development of gene therapy drugs for ophthalmic diseases and the research and development of gene editing technology and services, serving clinical researchers and healthcare providers to access targeted, long-acting gene therapies that reduce treatment frequency and improve precision in managing degenerative eye conditions.
- Sector
- Healthcare
- HQ
- Hefei, China
- Founded
- 2019
- Employees
- 2
- Website
- starrygene.com/
- Ownership
- Privately Held (backing)
Starry Gene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Starry Gene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Starry Gene in its N-PORT filings yet. We sweep new filings monthly.